Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
AssigneeAsahi Kasei Pharma Corporation
InventorBenson Fong
Life of this patent
Estimating the term…
Abstract
Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.
Claims8
A therapeutic combination comprising an effective amount of fasudil and bosentan.
A method for treating pulmonary arterial hypertension in a person in need of such treatment comprising administering to a person in need thereof a therapeutically effective amount of a combination of fasudil and bosentan.
Dependencies are inferred from the claim text.